Sanofi (SNY)

NASDAQ: SNY · IEX Real-Time Price · USD
45.93
-0.67 (-1.44%)
Apr 12, 2024, 4:00 PM EDT - Market closed
-1.44%
Market Cap 106.90B
Revenue (ttm) 51.60B
Net Income (ttm) 6.00B
Shares Out 2.33B
EPS (ttm) 2.29
PE Ratio 19.88
Forward PE 11.14
Dividend $2.04 (4.44%)
Ex-Dividend Date May 9, 2024
Volume 1,349,249
Open 45.98
Previous Close 46.60
Day's Range 45.83 - 46.16
52-Week Range 42.63 - 57.82
Beta 0.45
Analysts Hold
Price Target 55.00 (+19.75%)
Earnings Date Apr 25, 2024

About SNY

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines... [Read more]

Sector Healthcare
CEO Paul Hudson
Employees 86,088
Stock Exchange NASDAQ
Ticker Symbol SNY
Full Company Profile

Financial Performance

In 2023, Sanofi's revenue was 46.44 billion, an increase of 2.32% compared to the previous year's 45.39 billion. Earnings were 5.40 billion, a decrease of -35.49%.

Financial numbers in EUR Financial Statements

Analyst Forecast

According to one analyst, the rating for SNY stock is "Hold" and the 12-month stock price forecast is $55.0.

Price Target
$55.0
(19.75% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Meet Europe's Mag 18. Novo Nordisk Stock, ASML, and Others Can Rival the Mag Seven.

The Mag Seven stocks have powered gains in the U.S. market. Now, the hunt is on for an equivalent group of outperformers elsewhere.

4 days ago - Barrons

Sanofi - AGM 30.04.2024 - Availability of Preparatory documents

COMBINED GENERAL MEETING OF APRIL 30, 2024 AVAILABILITY OF PREPARATORY DOCUMENTS The Company's shareholders are invited to attend the Combined General Meeting to be held on Thursday April 30, 2024 at ...

5 days ago - GlobeNewsWire

Sanofi Announces Launch of Verorab® (Sanofi Inactivated Rabies Vaccine) in the UK for Pre-exposure and Post-exposure Prophylaxis of Rabies in All Age Groups

READING, U.K.--(BUSINESS WIRE)--Sanofi launches Verorab® (Sanofi Inactivated Rabies Vaccine) in the UK for pre-exposure and post-exposure prophylaxis of rabies in all age groups.

8 days ago - Business Wire

Diabetes drug similar to Ozempic helped slow progression of Parkinson's disease in small trial

The drug, made by Sanofi, is a GLP-1 like Novo Nordisk's blockbuster diabetes injection Ozempic and weight loss counterpart Wegovy

9 days ago - CNBC

Diabetes medication appears to slow progress of Parkinson's disease in French-backed trial

A Type 2 diabetes medication called lixisenatide appeared to slow the progression of Parkinson's disease symptoms in a small, mid-stage trial funded by the French Ministry of Health and others, the Ne...

Other symbols: LLYNVO
9 days ago - Market Watch

Sanofi to Settle Claims That Heartburn Drug Zantac Caused Cancer

The French healthcare company said the deal would require the consent of individual plaintiffs and would take time to conclude.

10 days ago - WSJ

Sanofi to settle 4,000 Zantac cancer lawsuits in US state courts

Sanofi has reached an agreement in principle to settle 4,000 lawsuits linking the discontinued heartburn drug Zantac to cancer, the company said on Wednesday.

10 days ago - Reuters

Press Release: Availability of the Q1 2024 Memorandum for modelling purposes

Availability of the Q1 2024 Memorandum for modelling purposes Paris, France – March 22, 2024. Sanofi announced today that its Q1 2024 Memorandum for modelling purposes is available on the "Investors" ...

22 days ago - GlobeNewsWire

Press Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis

New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis

4 weeks ago - GlobeNewsWire

Astra-Sanofi's RSV therapy 'highly effective' against infant hospitalizations, CDC study shows

AstraZeneca and Sanofi's antibody therapy was 90% effective in protecting infants from hospitalizations associated with respiratory syncytial virus (RSV), a study by the U.S. Centers of Disease Contro...

Other symbols: AZN
5 weeks ago - Reuters

‘GRANOLAS' vs. the Magnificent Seven: Which should you dig into now?

Wall Street loves a good story, as evidenced by the recent focus on a group of stocks called the “GRANOLAS.” These are a group of 11 European stocks that have led Europe's stock markets higher.

6 weeks ago - Market Watch

Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria

Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria Late-breaking data at 2024 AAAAI showed...

7 weeks ago - GlobeNewsWire

Press Release: Filing of the 2023 U.S. Form 20-F and French “Document d'Enregistrement Universel” containing the Annual Financial Report

Filing of the 2023 U.S. Form 20-F and French “Document d'Enregistrement Universel” containing the Annual Financial Report Paris, February 23, 2024. Sanofi announces today the filing of its Form 20-F w...

7 weeks ago - GlobeNewsWire

Press Release: Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation

Dupixent ® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation

Other symbols: REGN
7 weeks ago - GlobeNewsWire

Press Release: Sanofi's Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors

Sanofi's Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors

7 weeks ago - GlobeNewsWire

Sanofi's consumer healthcare spin-off attracts private equity interest, sources say

Drugmaker Sanofi's consumer healthcare division has attracted interest from private equity funds as the French group prepares to spin out the business, two sources close to the matter told Reuters.

7 weeks ago - Reuters

Blackstone may soon buy Sanofi's consumer health unit

Sanofi SA (EPA: SAN) is gaining at writing following a report that buyout firms have shown interest in buying its consumer health unit.

Other symbols: BX
7 weeks ago - Invezz

Denali-Sanofi's ALS drug fails to meet main goal of mid-stage trial

Denali Therapeutics said on Friday it was informed by partner Sanofi that their drug for a type of neurological disease did not meet the main goal in a mid-stage trial.

2 months ago - Reuters

Press Release: Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU)

Japan first in the world to approve Dupixent ® for chronic spontaneous urticaria (CSU) Approval based primarily on results from Phase 3 trial showing Dupixent significantly reduced itch compared to pl...

Other symbols: REGN
2 months ago - GlobeNewsWire

Goldman Sachs Says 'GRANOLAS' Stocks Are Set to Enjoy Further Gains

Large-cap European firms with a global footprint and strong balance sheets have outperformed the 'Magnificent Seven' US stocks and are poised for further gains, according to Sharon Bell, senior Europe...

2 months ago - Bloomberg Markets and Finance

Nervous About Nvidia, Tesla and the Magnificent 7? Look at Goldman's GRANOLAS.

Some of the biggest European stocks offer a better risk-adjusted return than the Magnificent 7, and that's not their only quality.

2 months ago - Barrons

This grouping of stocks has actually kept up with the Magnificent Seven, and with a lot less risk

For all the attention paid to the highflying tech giants dubbed the Magnificent Seven, there's another grouping that has kept right up with them, and with a lot lower risk.

2 months ago - Market Watch

INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Inhibrx, Inc. (N...

Other symbols: INBX
2 months ago - Business Wire

Medidata and Sanofi Vaccines Extend Collaboration to Improve Patient Centricity and Trial Efficiency

NEW YORK--(BUSINESS WIRE)--Medidata, a Dassault Systèmes company and leading provider of clinical trial solutions to the life sciences industry, and Sanofi Vaccines, today announced a collaboration to...

2 months ago - Business Wire

Press Release: Peer support, flexible work arrangements, salary for a year: Sanofi launches global program for employees affected by cancer and critical illnesses

Peer support, flexible work arrangements, salary for a year: Sanofi launches global program for employees affected by cancer and critical illnesses Paris, February 5, 2024. Sanofi today launches ‘Canc...

2 months ago - GlobeNewsWire